PeptiDream : Announces Upward Revision of Financial Forecasts(Press Release) (88KB)
January 18, 2023 at 12:20 pm IST
Share
News Release
January 18, 2023
PeptiDream Inc https://www.peptidream.com(Securities Code: 4587 TSE Prime Market)
PeptiDream Announces Upward Revision of Financial Forecasts
KANAGAWA, JAPAN - January 18, 2023 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter
"PeptiDream")(Tokyo: 4587) today announced that the business forecasts released on November 10, 2022 have been revised due to recent business trends, as follows.
1. Revised consolidated financial forecasts for FY2022 (January 1, 2022 to December 31, 2022)
(Units, million yen, %)
Profit
Core
Operating
Profit
attributable
Revenue
operating
before
to
profit
profit
tax
owners of
parent
Previous forecast (A)
24,500
6,600
6,100
6,000
4,200
Revised forecast (B)
26,800
9,400
-
-
-
Increase/Decrease
2,300
2,800
-
-
-
(B-A)
Change (%)
9.4
42.4
-
-
-
(Reference)
Actual Results for
9,422
4,093
4,066
3,803
2,573
FY2021
2. Reason for the revision
In FY2022, in the Drug Discovery and Development Business, the signing of new collaboration agreements for PDCs (Peptide Drug Conjugates) contributed to earnings greater than initially forecasted. As a result, revenue and core operating profit forecasts are revised to 26,800 million yen and 9,400 million yen, respectively, which amounts to 9.4% and 42.4% increases in revenue and core operating profit, respectively, from the initial forecasts. Items other than revenue and core operating profit are currently under review and will be disclosed when available.
*The above forecasts are based on information available as of the date of the announcement of this document. Actual results may differ from the forecasts due to various factors.
About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology,
state-of-the-arthighly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug conjugate (PDC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of
investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com
Inquiries:
PeptiDream Inc.
Contact: Yuko Okimoto, IR & Public Affairs
Email: y-okimoto@peptidream.com
Attachments
Original Link
Original Document
Permalink
Disclaimer
PeptiDream Inc. published this content on 18 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2023 06:49:06 UTC.
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).